Shinpoong Pharmaceutical Co.,Ltd (KRX:019170)
South Korea · Delayed Price · Currency is KRW 10,410
+160 (1.56%)
Last updated: Apr 8, 2026, 2:26 PM KST
KRX:019170 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 234,681 | 221,094 | 200,229 | 209,288 | 189,237 |
Other Revenue | - | - | - | -0 | - |
| 234,681 | 221,094 | 200,229 | 209,288 | 189,237 | |
Revenue Growth (YoY) | 6.14% | 10.42% | -4.33% | 10.60% | -4.30% |
Cost of Revenue | 132,010 | 139,290 | 119,951 | 131,315 | 111,850 |
Gross Profit | 102,671 | 81,804 | 80,277 | 77,973 | 77,388 |
Selling, General & Admin | 76,939 | 77,764 | 79,068 | 76,549 | 69,256 |
Research & Development | 10,443 | 17,879 | 42,277 | 30,383 | 17,334 |
Amortization of Goodwill & Intangibles | 540.74 | 969.42 | 1,182 | 1,358 | 1,496 |
Other Operating Expenses | -143.43 | 800.65 | 394.37 | 646.98 | 3,241 |
Operating Expenses | 88,416 | 98,833 | 127,670 | 111,992 | 91,694 |
Operating Income | 14,255 | -17,029 | -47,392 | -34,019 | -14,306 |
Interest Expense | -2,688 | -2,632 | -1,719 | -61.42 | -202.06 |
Interest & Investment Income | 767.26 | 704.06 | 1,174 | 1,026 | 1,878 |
Earnings From Equity Investments | - | - | -6,514 | -697.09 | 2,620 |
Currency Exchange Gain (Loss) | -1,232 | 2,833 | 1,328 | -1,009 | 406.81 |
Other Non Operating Income (Expenses) | 167.43 | 279.23 | 653.36 | -182.48 | 314.91 |
EBT Excluding Unusual Items | 11,269 | -15,844 | -52,471 | -34,942 | -9,288 |
Gain (Loss) on Sale of Investments | -2,820 | 1,215 | -1,011 | 845.62 | 253.64 |
Gain (Loss) on Sale of Assets | 2.54 | 6.89 | 39.65 | 18.31 | 49.02 |
Asset Writedown | - | - | - | -703.23 | - |
Pretax Income | 8,452 | -14,622 | -53,442 | -34,782 | -8,986 |
Income Tax Expense | 62.48 | 751.41 | 3,831 | 527.29 | 2,540 |
Earnings From Continuing Operations | 8,389 | -15,373 | -57,273 | -35,309 | -11,526 |
Minority Interest in Earnings | 435.95 | -13.8 | -52.86 | -68.14 | -57.61 |
Net Income | 8,825 | -15,387 | -57,325 | -35,377 | -11,584 |
Net Income to Common | 8,825 | -15,387 | -57,325 | -35,377 | -11,584 |
Shares Outstanding (Basic) | 51 | 51 | 51 | 51 | 51 |
Shares Outstanding (Diluted) | 51 | 51 | 51 | 51 | 51 |
Shares Change (YoY) | 0.37% | -0.28% | - | - | 1.85% |
EPS (Basic) | 172.00 | -301.00 | -1118.28 | -690.12 | -225.97 |
EPS (Diluted) | 172.00 | -301.00 | -1118.28 | -690.12 | -225.97 |
Free Cash Flow | 13,776 | -20,724 | -39,696 | -31,767 | -75,453 |
Free Cash Flow Per Share | 268.50 | -405.39 | -774.37 | -619.69 | -1471.90 |
Gross Margin | 43.75% | 37.00% | 40.09% | 37.26% | 40.89% |
Operating Margin | 6.07% | -7.70% | -23.67% | -16.25% | -7.56% |
Profit Margin | 3.76% | -6.96% | -28.63% | -16.90% | -6.12% |
Free Cash Flow Margin | 5.87% | -9.37% | -19.82% | -15.18% | -39.87% |
EBITDA | 25,648 | -5,066 | -35,484 | -21,215 | -1,631 |
EBITDA Margin | 10.93% | -2.29% | -17.72% | -10.14% | -0.86% |
D&A For EBITDA | 11,393 | 11,963 | 11,908 | 12,803 | 12,675 |
EBIT | 14,255 | -17,029 | -47,392 | -34,019 | -14,306 |
EBIT Margin | 6.07% | -7.70% | -23.67% | -16.25% | -7.56% |
Effective Tax Rate | 0.74% | - | - | - | - |
Advertising Expenses | 11,855 | 16,981 | 17,979 | 19,126 | 17,097 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.